Objective:

To highlight the importance of early screening and diagnosis of keratoconus (KC) to prevent vision loss and address the challenges in current detection methods.

Approach:

• Treatment Insights: Reviews the low rates of cross-linking therapy and discusses the significance of the recent FDA approval of epithelium-on, oxygen-enriched corneal cross-linking (Epioxa), which allows for earlier treatment without the need for documented progression.

Key Findings:

• About 70% of patients are diagnosed at moderate to advanced stages of KC, highlighting the need for earlier detection.
• Only about 12% of newly diagnosed patients receive cross-linking therapy, indicating a gap in treatment access.
• Early detection is crucial as changes in vision can be gradual and lead to significant loss if untreated.
• Certain groups, such as those with Down syndrome and sleep apnea, have elevated risk for KC.

Interpretation:

The article stresses the critical need for improved awareness and screening for keratoconus to facilitate early diagnosis and treatment, which can significantly alter patient outcomes.

Limitations:

• Current screening methods are not widely available in primary care settings, which limits early detection.
• Public awareness of keratoconus is low compared to other eye diseases, contributing to delayed diagnosis.

Conclusion:

Early diagnosis and treatment of keratoconus can prevent severe vision loss.